• BCL-2 Targeting in Heterogeneous Castration-Resistant Prosta

  2026-05-14

  This study integrates quantitative single-cell imaging, mechanistic modeling, and a Phase Ib clinical trial to reveal BCL-2 as a shared vulnerability in heterogeneous castration-resistant prostate cancer (CRPC). The findings clarify how androgen receptor (AR) inhibition induces BCL-2 upregulation and support combined AR and BCL-2 targeting strategies for overcoming therapeutic resistance.

• Entecavir (BMS200475): Molecular Selectivity and Clinical Im

  2026-05-13

  Explore the molecular selectivity of Entecavir, a potent inhibitor for chronic hepatitis B virus replication, and discover how recent evidence guides its application in therapy and advanced research. This article offers unique insights into Entecavir’s mechanism, resistance profile, and assay optimization strategies.

• FITC-Concanavalin A (ConA) Conjugate: Practical Research Gui

  2026-05-13

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose moieties on cell surfaces, supporting workflows in immunofluorescence, flow cytometry, and glycobiology. This reagent is not recommended for non-carbohydrate-binding applications or use beyond its defined stability window.

• Iron Stress Alters Enterocyte Metabolism and Immune Signalin

  2026-05-12

  Navazesh and Ji's 2025 study reveals how iron deficiency and excess distinctly reprogram metabolism and immune gene expression in IPEC-J2 enterocytes. These findings clarify the cellular mechanisms underlying iron imbalance in the gut and offer reference points for future metabolic and apoptosis research in epithelial models.

• DAPI Solution (1 mg/mL): Workflow-Driven Nuclear Visualizati

  2026-05-12

  DAPI Solution (1 mg/mL) from APExBIO delivers reproducible, high-contrast nuclear visualization and apoptosis detection in fixed and compromised cells. This guide translates recent mechanistic insights and published workflows into actionable protocols and troubleshooting strategies for advanced research applications.

• Mitochondrial Apoptosis and Muscle Atrophy in Ovarian Cancer

  2026-05-11

  This study investigates the relationship between mitochondrial hydrogen peroxide emission, apoptotic and necroptotic signaling, and skeletal muscle atrophy in a mouse model of metastatic ovarian cancer. The findings demonstrate that while the mitochondrial-targeted antioxidant SkQ1 effectively reduces mitochondrial-mediated apoptosis markers, it does not prevent muscle atrophy, suggesting apoptosis and necroptosis are not primary drivers in this context.

• TPCA-1: Unraveling IKK-2 Inhibition for Cytokine Modulation

  2026-05-11

  Explore how TPCA-1, a potent IKK-2 inhibitor, provides unique mechanistic insights into selective cytokine regulation and NF-κB pathway modulation. This article delves deeper into the intersection of kinase inhibition, cell death, and inflammation research than existing resources.

• MG-132 (Z-LLL-al): Precision Autophagy Modulation for Cancer

  2026-05-10

  Discover how MG-132 (Z-LLL-al) uniquely enables high-resolution autophagy and apoptosis assays in cancer research. This article delivers advanced insights into its mechanism, protocol optimization, and the translational significance of mTOR pathway targeting.

• Selective β1 Blockade Preserves Hematopoietic Regeneration P

  2026-05-09

  This study demonstrates that nonselective β-adrenergic receptor inhibitors, unlike β1-selective agents, significantly impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in mice and humans. The findings highlight the importance of β-blocker selectivity in clinical and research settings involving hematopoietic recovery.

• Estradiol–Autophagy Axis in Organ Protection During Perimeno

  2026-05-09

  This study elucidates how declining estradiol during perimenopause elevates cardiometabolic and renal risk, demonstrating that estrogen receptor–mediated autophagy is central to multi-organ protection. Integrated human cohort analysis, network pharmacology, and mouse modeling reveal mechanistic detail and inform precision research strategies for estrogen signaling.

• Combating TNBC: XPO1 Inhibition and Synergistic Combinations

  2026-05-08

  This study identifies nuclear export inhibition, specifically via KPT-330 (Selinexor), as a promising strategy for treating basal-like triple-negative breast cancer (TNBC). Preclinical models reveal potent synergy when KPT-330 is combined with PI3K/mTOR inhibition, providing a rationale for new targeted combination therapies in resistant TNBC.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-05-07

  This study demonstrates that naturally occurring angiotensin peptides, including Angiotensin (1-7), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings provide new insight into the molecular interplay between the renin–angiotensin system and viral entry, with implications for understanding COVID-19 pathogenesis and therapeutic targeting.

• Panobinostat Targets Epigenetic Vulnerabilities in MLL-ALL

  2026-05-07

  This study demonstrates that the HDAC inhibitor panobinostat exerts potent anti-leukemic activity against MLL-rearranged acute lymphoblastic leukemia (ALL) in vivo, mediated in part by suppression of the RNF20/RNF40/WAC-H2B ubiquitination axis. The findings highlight a promising therapeutic approach targeting epigenetic dysregulation in infant MLL-ALL, with implications for apoptosis and cell fate analysis.

• Cisplatin (CDDP): Precision Apoptosis Control and Overcoming

  2026-05-06

  Explore the advanced use of Cisplatin (CDDP) in cancer research, focusing on apoptosis regulation and strategies for overcoming chemotherapy resistance. This article reveals new mechanistic insights and practical protocols to maximize experimental reproducibility.

• FOXM1 Inhibition via Autophagic Degradation Overcomes Chemor

  2026-05-06

  The referenced study identifies STL427944 as a highly selective small-molecule inhibitor of FOXM1, a transcription factor central to cancer chemoresistance. By inducing autophagic degradation of FOXM1, STL427944 sensitizes tumor cells to standard chemotherapies, including taxanes, highlighting a promising avenue for improving cancer treatment outcomes.

448 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page